Trump signs order to ensure 'resilient' supply chain for essential medicines in US
The Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services is tasked with developing a list of about 26 critical drugs vital to 'national health and security', the White House said in a fact sheet.
'The Order directs the Office ... and ready the SAPIR repository to receive and maintain the Active Pharmaceutical Ingredients (APIs) used to make these critical drugs.' - REUTERS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
3 days ago
- The Sun
Trump signs order to ensure 'resilient' supply chain for essential medicines in US
U.S. PRESIDENT Donald Trump signed an executive order aimed at ensuring a 'resilient' supply chain for essential medicines in the U.S. by filling the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with critical drug components, the White House said on Wednesday. The Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services is tasked with developing a list of about 26 critical drugs vital to 'national health and security', the White House said in a fact sheet. 'The Order directs the Office ... and ready the SAPIR repository to receive and maintain the Active Pharmaceutical Ingredients (APIs) used to make these critical drugs.' - REUTERS
Free Malaysia Today
07-08-2025
- Free Malaysia Today
Australia worried by Trump's threat to raise US pharma tariffs to 250%
US President Donald Trump said the US would first impose a 'small' tariff on foreign-made drugs before hiking it to 150% and eventually to 250%. (AP pic) SYDNEY : Australia is very concerned about US President Donald Trump's latest threat to raise tariffs on pharmaceutical imports by up to 250% over the longer term, its health minister said today. Trump said this week that the US would first impose a 'small' tariff on foreign-made drugs before hiking it to 150% within 18 months and eventually to 250% in an effort to boost domestic production. Mark Butler said the plan would be a blow to producers such as CSL, Australia's largest biotech company. 'And that is why we are working so hard to press the case for the continuation of free trade,' he told reporters. Medicines and pharmaceuticals are among Australia's top exports to the US, with around A$2.1 billion (US$1.4 billion) in shipments last year, according to the Australian Bureau of Statistics. There has been some bilateral tension over drug pricing in Australia. In a January submission to the US government, the Pharmaceutical Research and Manufacturers of America trade group said Australia's Pharmaceutical Benefits Scheme was 'egregious and discriminatory' and 'undervalued American innovation,' putting jobs and exports at risk. Butler said the national programme, which subsidises a wide range of prescription medicines for Australians, would not be changed to appease American companies and escape the threatened tariffs. 'To the extent that this is motivated by big pharma companies seeking to lobby the US administration to water down the protections of our PBS, it's simply not up for negotiation under our government,' he said.
The Star
05-08-2025
- The Star
Pfizer reports strong Q2 revenue
NEW YORK, Aug. 5 (Xinhua) -- U.S. pharmaceutical company Pfizer announced its second-quarter earnings on Tuesday, reporting a 10 percent year over year operational growth. The financial results posted by the New York-headquartered company represent revenue of 14.7 billion U.S. dollars or 0.51 dollars of earnings per share. In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of 2.80 dollars to 3.00 dollars. The company maintained its annual revenue projection of 61 billion to 64 billion dollars, reflecting confidence in its underlying business performance. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement. Pfizer's strong performance came amid mounting policy pressures from the White House. U.S. President Donald Trump has recently sent letters to 17 pharmaceutical companies, including Pfizer, demanding that they cut prices on all existing medications for Medicaid patients to levels no higher than those in Europe. During Tuesday's earnings call, Bourla acknowledged that the company received the letter from the Trump administration. However, he declined to elaborate on the policy's specific impacts, although he emphasized that discussions with the administration have been "extremely productive." Pfizer's Q2 results were bolstered by rising sales in several key product categories. Its Vyndaqel line of cardiomyopathy treatments showed solid growth, and COVID-19-related products were major contributors.
